Donor ABCB1 genetic polymorphisms influence epithelial-to-mesenchyme transition in tacrolimus-treated kidney recipients

Pharmacogenomics

Volumn 15, Issue 16, 2014, Pages 2011-2024

  Bloch, Julie ^a,b   Hazzan, Marc ^b   Van Der Hauwaert, Cynthia ^a   Buob, David ^b   Savary, Grégoire ^a   Hertig, Alexandre ^c   Gnemmi, Viviane ^b   Frimat, Marie ^b   Perrais, Michaël ^d   Copin, Marie Christine ^b   Broly, Franck ^a   Noël, Christian ^b   Pottier, Nicolas ^a   Cauffiez, Christelle ^a   Glowacki, François ^a,b  

^a UFR3S Pharmacie   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c HÔPITAL TENON   (France)

^d INSERM   (France)

Author keywords

ABCB1; CYP3A5; epithelial mesenchymal transition; fibrosis; tacrolimus

Indexed keywords

BETA CATENIN; CYTOCHROME P450 3A5; TACROLIMUS; VIMENTIN;

ABCB1 GENE; ADULT; ARTICLE; CYP3A5 1 GENE; CYP3A5 GENE; DRUG DISPOSITION; DRUG RESPONSE; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FIBROSING ALVEOLITIS; GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; GRAFT RECIPIENT; HAPLOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY FIBROSIS; KIDNEY TUBULE CELL; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84919818886     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.146     Document Type: Article

References (50)

1. Vitalone MJ, Naesens M, Sigdel T, Li L, Hseih S, Sarwal MM. The dual role of epithelial-To-mesenchymal transition in chronic allograft injury in pediatric renal transplantation. Transplantation 92(7), 787-795 (2011
2. Brouard S, Renaudin K, Soulillou JP. Revisiting the natural history of IF/TA in renal transplantation. Am. J. Transplant. 11(4), 647-649 (2011
3. Nankivell BJ, Borrows RJ, Fung CL, OConnell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N. Engl. J. Med. 349(24), 2326-2333 (2003
4. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am. J. Transplant. 9(3), 527-535 (2009
5. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat. Rev. Nephrol. 7(12), 684-696 (2011
6. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119(6), 1420-1428 (2009
7. Slattery C, Campbell E, McMorrow T, Ryan MP. Cyclosporine A-induced renal fibrosis: a role for epithelial-mesenchymal transition. Am. J. Pathol. 167(2), 395-407 (2005
8. Hertig A, Verine J, Mougenot B, et al. Risk factors for early epithelial to mesenchymal transition in renal grafts. Am. J. Transplant. 6(12), 2937-2946 (2006
9. Vongwiwatana A, Tasanarong A, Rayner DC, Melk A, Halloran PF. Epithelial to mesenchymal transition during late deterioration of human kidney transplants: the role of tubular cells in fibrogenesis. Am. J. Transplant. 5(6), 1367-374 (2005
10. Hertig A, Anglicheau D, Verine J, et al. Early epithelial phenotypic changes predict graft fibrosis. J. Am. Soc. Nephrol. 19(8), 1584-1591 (2008
11. de Matos AC, Câmara NO, Tonato EJ, et al. Vimentin expression and myofibroblast infiltration are early markers of renal dysfunction in kidney transplantation: an early stage of chronic allograft dysfunction?. Transplant. Proc. 42(9), 3482-3488 (2010
12. Galichon P, Vittoz N, Xu-Dubois YC, et al. Epithelial phenotypic changes detect cyclosporine in vivo nephrotoxicity at a reversible stage. Transplantation 92(9), 993-998 (2011
13. Hazzan M, Hertig A, Buob D, et al. Epithelial-To-mesenchymal transition predicts cyclosporine nephrotoxicity in renal transplant recipients. J. Am. Soc. Nephrol. 22(7), 1375-1381 (2011
14. Djamali A, Reese S, Hafez O, et al. Nox2 is a mediator of chronic CsA nephrotoxicity. Am. J. Transplant. 12(8), 1997-2007 (2012
15. Snanoudj R, Royal V, Elie C, et al. Specificity of histological markers of long-Term CNI nephrotoxicity in kidney-Transplant recipients under low-dose cyclosporine therapy. Am. J. Transplant. 11(12), 2635-2646 (2011
16. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin. J. Am. Soc. Nephrol. 4(2), 481-508 (2009
17. Staat CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin. Pharmacokinet. 49(3), 141-175 (2010
18. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N. Engl. J. Med. 348(6), 538-549 (2003
19. Gottlieb B, Chalifour LE, Mitmaker B, et al. BAK1 gene variation and abdominal aortic aneurysms. Hum. Mutat. 30(7), 1043-1047 (2009
20. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann. Intern. Med. 145(4), 247-254 (2006
21. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am. J. Transplant. 8(4), 753-760 (2008
22. Lin DY, Zeng D, Millikan R. Maximum likelihood estimation of haplotype effects and haplotype-environment interactions in association studies. Genet. Epidemiol. 29(4), 299-312 (2005
23. Jeannesson E, Albertini L, Siest G, et al. Determination of ABCB1 polymorphisms and haplotypes frequencies in a French population. Fundam. Clin. Pharmacol. 21(4), 411-418 (2007
24. Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5(3), 243-272 (2004
25. Broecker V, Mengel M. The significance of histological diagnosis in renal allograft biopsies in 2014. Transpl. Int. doi: 10.1111/tri.12446 (2014) (Epub ahead of print
26. Kriz W, Kaissling B, Le Hir. Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy?. J. Clin. Invest. 121(2), 468-474 (2011
27. Prunotto M, Budd DC, Gabbiani G, et al. Epithelial-mesenchymal crosstalk alteration in kidney fibrosis. J. Pathol. 228(2), 131-147 (2012
28. Humphreys BD, Lin SL, Kobayashi A, et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am. J. Pathol. 176(1), 85-97 (2010
29. Zeisberg M, Duffield JS. Resolved. EMT produces fibroblasts in the kidney. J. Am. Soc. Nephrol. 21(8), 1247-1253 (2010
30. Galichon P, Hertig A. Epithelial to mesenchymal transition as a biomarker in renal fibrosis: are we ready for the bedside?. Fibrogenesis Tissue Repair 4, 11 (2011
31. Xu-Dubois YC, Baugey E, Peltier J. Epithelial phenotypic changes are associated with a tubular active fibrogenic process in human renal grafts. Hum. Pathol. 44(7), 1251-1261 (2013
32. Mengel M, Sis B, Haas M, et al. Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am. J. Transplant. 12(3), 563-570 (2012
33. Glowacki F, Lionet A, Hammelin JP, et al. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients. Clin. Pharmacokinet. 50(7), 451-459 (2011
34. Srinivas TR, Meier-Kriesche HU. Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result. Clin. J. Am. Soc. Nephrol. 3(Suppl. 2), S101-S116 (2008
35. Naesens M, Lerut E, Damme BV, Vanrenterghem Y, Kuypers DR. Tacrolimus exposure and evolution of renal allograft histology in the first year after transplantation. Am. J. Transplant. 7(9), 2114-2123 (2007
36. Iwasaki K, Shiraga T, Matsuda H. Absorption, distribution, metabolism and excretion of tacrolimus (FK506) in the rat. Drug Metab. Pharmacokinet. 13, 259-265 (2008
37. Metalidis C, Lerut E, Naesens M, Kuypers DR. Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity. Transplantation 91(10), 1098-1102 (2011
38. Joy MS, Hogan SL, Thompson BD, Finn WF, Nickeleit V. Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity. Nephrol. Dial Transplant. 22(7), 1963-1968 (2007
39. Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315(5811), 525-528 (2007
40. Hauser IA, Schaeffeler E, Gauer S, et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J. Am. Soc. Nephrol. 16(5), 1501-1511 (2005
41. Woillard JB, Rerolle JP, Picard N, et al. Donor P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long-Term follow-up. Clin. Pharmacol. Ther. 88(1), 95-100 (2010
42. Naesens M, Lerut E, de Jonge H, Van Damme B, Vanrenterghem Y, Kuypers DR. Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts. J. Am. Soc. Nephrol. 20(11), 2468-2480 (2009
43. Moore J, McKnight AJ, Döhler B, et al. Donor ABCB1 variant associates with increased risk for kidney allograft failure. J. Am. Soc. Nephrol. 23(11), 1891-1899 (2012
44. Hauser IA, Kruck S, Gauer S, et al. Human pregnane X receptor genotype of the donor but not of the recipient is a risk factor for delayed graft function after renal transplantation. Clin. Pharmacol Ther. 91(5), 905-916 (2012
45. Elens L, van Gelder T, Hesselink DA, Haufroid V, van Schaik RH. CYP3A4 22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. Pharmacogenomics 14(1), 47-62 (2013
46. Elens L, Hesselink DA, Bouamar R, et al. Impact of POR 28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients. Ther. Drug Monit. 36(1), 71-79 (2014
47. Elens L, Bouamar R, Hesselink DA, et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin. Chem. 57(11), 1574-1583 (2011
48. Elens L, Capron A, van Schaik RH, et al. Impact of CYP3A4 22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines. Ther. Drug Monit. 35(5), 608-616 (2013
49. Elens L, Bouamar R, Hesselink DA, Haufroid V, van Gelder T, van Schaik RH. The new CYP3A4 intron 6 C T polymorphism (CYP3A4 22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-Treated kidney transplant patients. Pharmacogenet. Genomics 22(5), 373-380 (2012
50. Hesselink DA, Bouamar R, Elens L, van Schaik RH, van Gelder T. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. Clin. Pharmacokinet. 53(2), 123-139 (2014